An economic model to assess the savings from a clinical application of haematopoietic growth factors.
Patients receiving chemotherapy frequently develop fever and neutropenia. Haematopoietic growth factors (HGFs) may decrease the duration of such episodes or may prevent a febrile neutropenic episode. In this study we introduce a Markov type economic model for the hospital which calculates all relevant direct costs and savings of HGF therapy and may support decisions on HGF administration. A distinction is made between patients receiving intensive and standard chemotherapy schedules. Our results indicate that HGFs can induce savings in intensive chemotherapy and standard chemotherapy following neutropenic fever. Prophylactic administration of HGF is cost-effective if the risk of infection is considerable. The risk of infection depends on underlying malignancy, corresponding treatment modalities and the health condition of the patient. The model is meant as an analytical framework and should be used carefully, as not all benefits (e.g. benefits to the patients) are considered. These benefits may be balanced against the additional costs or savings resulting from the economic model.
Uyl-de Groot
C A
CA
Institute for Medical Technology Assessment/Institute for Health Care Policy and Management, Erasmus University Rotterdam, Netherlands.
Vellenga
E
E
Rutten
F F
FF
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016527:Drug Costs; D005334:Fever / Q000191:economics / Q000517:prevention & control*; D016298:Hematopoietic Cell Growth Factors / Q000191:economics* / Q000627:therapeutic use; D017721:Hospital Costs; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D009369:Neoplasms / Q000188:drug therapy*; D009426:Netherlands; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors